You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

NSCLC

Showing 1 - 25 of 5,153
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Clinical Implications for NSCLC Patients With Rare Mutations

Recruiting
  • NSCLC
  • +2 more
    • Shanghai, Shanghai, China
    • +1 more
    Jan 18, 2023

    NSCLC, Stage III Trial in Beijing (Tislelizumab, Pemetrexed (Nonsquamous NSCLC) or Paclitaxel/Nab-paclitaxel(Squamous NSCLC),

    Recruiting
    • NSCLC, Stage III
    • Beijing, Beijing, China
      Beijing Tsinghua Chang Gung Hospital
    Nov 4, 2022

    NSCLC Trial (Atezolizumab, Tiragolumab)

    Not yet recruiting
    • NSCLC
    • (no location specified)
    Apr 5, 2023

    Using Ex Vivo Tumoroids To Predict Immunotherapy Response In

    Recruiting
    • Lung Cancer
    • +2 more
    • Standard of care immune checkpoint inhbitors
    • Fairway, Kansas
    • +1 more
    Sep 19, 2022

    NSCLC Trial (Lazertinib group)

    Not yet recruiting
    • NSCLC
    • Lazertinib group
    • (no location specified)
    Jul 14, 2022

    Non Small Cell Lung Cancer, EGFR Gene Mutation, Immune Checkpoint Inhibitor Trial in Jerusalem (concomitant TTFields treatment

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • +2 more
    • concomitant TTFields treatment device to standard of care EGFR positive NSCLC treatment
    • concomitant TTFields treatment device to standard of care anti PD-1 NSCLC treatment
    • Jerusalem, Israel
      Shaare Zedek Medical Center
    Jan 22, 2023

    NSCLC With COPD Trial in Tianjin (Pembrolizumab)

    Recruiting
    • NSCLC With COPD
    • Tianjin, China
      Tianjin Chest Hospital
    Oct 10, 2022

    Locally Advanced or Metastatic NSCLC Trial in Ohio City (PBF-1129)

    Active, not recruiting
    • Locally Advanced or Metastatic NSCLC
    • Ohio City, Ohio
      Division of medical Oncology A450B Starling Loving Hall
    Jan 24, 2023

    High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1

    Suspended
    • NSCLC Stage IV
    • NSCLC, Stage IIIC
    • Primary Immune Response (PIR) test by Biodesix, Inc.
    • San Carlos, California
    • +1 more
    Jan 26, 2023

    NSCLC Trial in Changsha (AK104+anlotinib)

    Active, not recruiting
    • NSCLC
    • Changsha, Hunan, China
      Hunan cancer hospital
    May 18, 2022

    NSCLC, NSCLC Trial in Bronx (PembroRT, ChemoRT)

    Active, not recruiting
    • Non-small Cell Lung Cancer, NSCLC
    • Bronx, New York
      Montefiore Medical Center
    Dec 6, 2022

    A Chart Review Study of Adults With Advanced NSCLC

    Not yet recruiting
    • Non-small Cell Lung Cancer (NSCLC)
      • (no location specified)
      Aug 1, 2022

      Non Small Cell Lung Cancer, NSCLC, Stage III, Nsclc Trial in Stanford (Durvalumab, Carboplatin, Pemetrexed)

      Recruiting
      • Non Small Cell Lung Cancer
      • +2 more
      • Stanford, California
        Stanford University
      Oct 27, 2022

      NSCLC Stage IV Trial in New York (Pembrolizumab, Radiation, Chemotherapy)

      Recruiting
      • NSCLC Stage IV
      • New York, New York
        NYU Langone Health
      Jan 11, 2023

      NSCLC, Stage I Trial in Tianjin (Osimertinib)

      Recruiting
      • NSCLC, Stage I
      • Tianjin, Tianjin, China
        Tianjin Medical University Cancer Institute & Hospital
      Jan 6, 2023

      Lung Cancer, NSCLC Stage IV, Metastatic NSCLC - NSCLC Trial in Kansas City, Overland Park, Lee's Summit (Cabozantinib,

      Not yet recruiting
      • Lung Cancer
      • +3 more
      • Kansas City, Kansas
      • +3 more
      May 12, 2023

      Significance of MRD After Surgery in Driver Gene-positive and

      Enrolling by invitation
      • NSCLC MRD ctDNA
        • Shenzhen, China
          ShenzhenPH
        Jun 30, 2022

        ICIs Plus Angiogenesis Inhibitors for Treatment of Advanced

        Completed
        • NSCLC
        • Immune checkpoint inhibitors plus angiogenesis inhibitors
        • Immune checkpoint inhibitors without angiogenesis inhibitors
        • Suzhou, Jiangsu, China
          The Affiliated Suzhou Hospital of Nanjing Medical University
        Jan 17, 2023

        NSCLC (NSCLC) Trial in New York (Pembrolizumab)

        Not yet recruiting
        • Non-Small Cell Lung Cancer (NSCLC)
        • New York, New York
          Mount Sinai Hospital
        Jan 23, 2023

        NSCLC Trial in Worldwide (Afatinib)

        Completed
        Has Results
        • NSCLC
        • Köln, Germany
        • +4 more
        Aug 23, 2022

        NSCLC Stage IV Trial in Hangzhou (SBRT)

        Recruiting
        • NSCLC Stage IV
        • SBRT
        • Hangzhou, Zhejiang, China
          Zhejiang Cancer Hospital
        May 22, 2022

        NSCLC Trial in Singapore (Oral S-1 + Oral Osimertinib)

        Not yet recruiting
        • NSCLC
        • Oral S-1 + Oral Osimertinib
        • Singapore, Singapore
          National Cancer Center Singapore
        Mar 6, 2023

        NSCLC Trial (PM8002, Placebo, Carboplatin)

        Not yet recruiting
        • NSCLC
        • (no location specified)
        Feb 23, 2023

        Non-squamous NSCLC Trial (biological, drug, dietary supplement)

        Not yet recruiting
        • Non-squamous NSCLC
        • Pembrolizumab
        • +7 more
        • (no location specified)
        Feb 20, 2023

        NSCLC, NSCLC, PD-1 Trial in Beijing (F520, Pemetrexed, Carboplatin)

        Not yet recruiting
        • Non-small Cell Lung Cancer
        • +2 more
        • Beijing, China
          Cancer Hospital, Chinese Academy of Medical Sciences
        Feb 22, 2023